ArticleAnnals of hematology2024

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).

Susanne Isfort et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.